Literature DB >> 9135028

Pharmacological options in the treatment of benign prostatic hyperplasia.

B Kenny1, S Ballard, J Blagg, D Fox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9135028     DOI： 10.1021/jm960697s

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  7 in total

1.  Modelling of adrenoceptor ligand targets based on novel medium- or macro-sized fused nitrogen heterocyclic systems.

Authors:  R Griffith; J B Bremner
Journal:  J Comput Aided Mol Des       Date:  1999-01       Impact factor: 3.686

2.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

3.  Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.

Authors:  Masahiko Terakado; Hidehiro Suzuki; Kazuya Hashimura; Motoyuki Tanaka; Hideyuki Ueda; Hiroshi Kohno; Taku Fujimoto; Hiroshi Saga; Shinji Nakade; Hiromu Habashita; Yoshikazu Takaoka; Takuya Seko
Journal:  ACS Med Chem Lett       Date:  2016-08-19       Impact factor: 4.345

4.  alpha-Blocker Therapy: Current Update.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2005

5.  Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2.

Authors:  Lifei Liu; Junming Wang; Liqin Zhao; Jon Nilsen; Kelsey McClure; Karren Wong; Roberta Diaz Brinton
Journal:  Endocrinology       Date:  2009-04-09       Impact factor: 4.736

6.  Pharmacological characterization of unique prazosin-binding sites in human kidney.

Authors:  Yasuko Hiraoka; Takanobu Taniguchi; Takashi Tanaka; Kenichiro Okada; Hiroshi Kanamaru; Ikunobu Muramatsu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-25       Impact factor: 3.000

Review 7.  The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression.

Authors:  Abdulmaged M Traish; Ashwini Mulgaonkar; Nicholas Giordano
Journal:  Korean J Urol       Date:  2014-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.